Tempus AI (TEM) news
Recent news
Tempus AI, Inc.: Canaccord Genuity raises target price to $95 from $80
Canaccord Genuity has raised its price target for Tempus AI, Inc. (TEM) to $95 from $80, reflecting a more bullish outlook for the healthcare technology company. This adjustment aligns with recent developments, including the company’s first-quarter GAAP profitability, FDA approval for a key…
AInvest Wire · 3d agoTempus: To manage collection & transfer of tumor tissue & blood samples needed for next-generation sequencing
Tempus, a company specializing in next-generation sequencing (NGS) for cancer research and diagnostics, plays a critical role in the collection and transfer of tumor tissue and blood samples required for genomic analysis. These samples are essential for generating comprehensive molecular profiles…
AInvest Wire · Oct 7, 2026Tempus - Announces expanded multi-year collaboration for Intismeran autogene commercialization
AInvest Wire · Oct 7, 2026Tempus - Financial terms of collaboration not disclosed
AInvest Wire · Oct 7, 2026Personalis, Inc. - HSR waiting period expired October 2, 2026 for Tempus AI merger - SEC filing
The Hart-Scott-Rodino (HSR) waiting period related to Tempus AI’s proposed acquisition of Personalis, Inc. expired on October 2, 2026, according to a recent SEC filing. This development marks a key procedural milestone in the merger process, indicating that regulatory scrutiny under the HSR Act has…
AInvest Wire · Oct 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.